
Global & Colombia Cancer Therapeutics Market to 2031
Description
According to GLOBOCAN data, Colombia reported approximately 120,000 new cancer cases in 2022, with breast and prostate cancers being the most frequently diagnosed. This increasing cancer burden has driven a strong demand for advanced treatments, including chemotherapy and targeted therapies, to manage various cancer types such as breast cancer. In response, the Colombian government has implemented several measures to enhance cancer care and improve patient access to therapies. The National Cancer Institute of Colombia, founded by the Ministry of Health in 1934, focuses on providing comprehensive cancer control through patient care, research, healthcare workforce training, and public health initiatives. Additionally, in 2016, Colombia launched the Policy and Comprehensive Health Care Pathways, which includes a specialized cancer pathway addressing health promotion, early diagnosis, timely treatment, rehabilitation, and follow-up, while also considering social determinants of health.
International pharmaceutical companies are actively expanding their operations in Colombia. For instance, in March 2024, the ChemRar Group of Companies signed a supply agreement with Pharmaceutical Health Corporation S.A.S., Colombia’s national medicine distributor, to introduce five new cancer drugs: Temozolomide, Lantoger (gefitinib), Sunitinib-Chimrar (sunitinib), Potarbin (pazopanib), and Lapatinib-Chimrar (lapatinib). Moreover, in January 2022, Biotoscana Farma S.A., the Colombian branch of Knight Therapeutics Inc., secured approval from INVIMA for Lenvima (lenvatinib), developed by Eisai of Japan. This medication is used to treat radioiodine-refractory differentiated thyroid cancer (RR-DTC) and unresectable hepatocellular carcinoma (u-HCC).
International pharmaceutical companies are actively expanding their operations in Colombia. For instance, in March 2024, the ChemRar Group of Companies signed a supply agreement with Pharmaceutical Health Corporation S.A.S., Colombia’s national medicine distributor, to introduce five new cancer drugs: Temozolomide, Lantoger (gefitinib), Sunitinib-Chimrar (sunitinib), Potarbin (pazopanib), and Lapatinib-Chimrar (lapatinib). Moreover, in January 2022, Biotoscana Farma S.A., the Colombian branch of Knight Therapeutics Inc., secured approval from INVIMA for Lenvima (lenvatinib), developed by Eisai of Japan. This medication is used to treat radioiodine-refractory differentiated thyroid cancer (RR-DTC) and unresectable hepatocellular carcinoma (u-HCC).
Table of Contents
100 Pages
- 1. Introduction
- 1.1 Report Guidance
- 1.2 Market Segmentation
- 2. Executive Summary
- 2.1 Key Insights
- 3. Research Methodology
- 3.1 Secondary Research
- 3.2 Primary Research
- 3.2.1 Data Triangulation and Validation:
- 4. Colombia Cancer Therapeutics Market Landscape
- 4.1 Overview
- 4.2 Ecosystem Analysis
- 4.2.1 List of Vendors in the Value Chain
- 5. Cancer Therapeutics Market Key Market Dynamics
- 5.1 Cancer Therapeutics Market – Key Market Dynamics
- 5.2 Market Drivers
- 5.3 Market Restraints
- 5.4 Market Opportunities
- 5.5 Future Trends
- 5.6 Impact of Drivers and Restraints
- 6. Colombia Cancer Therapeutics Market – Analysis
- 6.1 Colombia Cancer Therapeutics Market Revenue (US$ Million), 2021–2031
- 6.2 Colombia Cancer Therapeutics Market Revenue and Forecast Analysis
- 7. Colombia Cancer Therapeutics Market Analysis – by Therapy Types
- 7.1 Colombia Cancer Therapeutics Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Therapy Types
- 8. Colombia Cancer Therapeutics Market Analysis – by Indications
- 8.1 Colombia Cancer Therapeutics Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Indications
- 9. Colombia Cancer Therapeutics Market Analysis – by Distribution Channel
- 9.1 Colombia Cancer Therapeutics Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Distribution Channel
- 10. Competitive Landscape
- 10.1 Heat Map Analysis by Key Players
- 10.1 Company Positioning and Concentration
- 11. Industry Landscape
- 11.1 Overview
- 11.2 Market Initiative
- 11.2 Partnerships and Collaborations
- 11.2 Other Developments
- 12. Company Profiles
- 12.1 Bristol-Myers Squibb Co
- 12.1. 1 Key Facts
- 12.1. 2 Business Description
- 12.1. 3 Products and Services
- 12.1. 4 Financial Overview
- 12.1. 5 SWOT Analysis
- 12.1. 6 Key Developments
- 12.2 AbbVie Inc
- 12.2. 1 Key Facts
- 12.2. 2 Business Description
- 12.2. 3 Products and Services
- 12.2. 4 Financial Overview
- 12.2. 5 SWOT Analysis
- 12.2. 6 Key Developments
- 12.3 Johnson & Johnson
- 12.3. 1 Key Facts
- 12.3. 2 Business Description
- 12.3. 3 Products and Services
- 12.3. 4 Financial Overview
- 12.3. 5 SWOT Analysis
- 12.3. 6 Key Developments
- 12.4 F. Hoffmann-La Roche Ltd
- 12.4. 1 Key Facts
- 12.4. 2 Business Description
- 12.4. 3 Products and Services
- 12.4. 4 Financial Overview
- 12.4. 5 SWOT Analysis
- 12.4. 6 Key Developments
- 12.5 Pfizer Inc
- 12.5. 1 Key Facts
- 12.5. 2 Business Description
- 12.5. 3 Products and Services
- 12.5. 4 Financial Overview
- 12.5. 5 SWOT Analysis
- 12.5. 6 Key Developments
- 12.6 AstraZeneca Plc
- 12.6. 1 Key Facts
- 12.6. 2 Business Description
- 12.6. 3 Products and Services
- 12.6. 4 Financial Overview
- 12.6. 5 SWOT Analysis
- 12.6. 6 Key Developments
- 12.7 Merck KGaA
- 12.7. 1 Key Facts
- 12.7. 2 Business Description
- 12.7. 3 Products and Services
- 12.7. 4 Financial Overview
- 12.7. 5 SWOT Analysis
- 12.7. 6 Key Developments
- 12.8 Novartis AG
- 12.8. 1 Key Facts
- 12.8. 2 Business Description
- 12.8. 3 Products and Services
- 12.8. 4 Financial Overview
- 12.8. 5 SWOT Analysis
- 12.8. 6 Key Developments
- 12.9 Astellas Pharma Inc
- 12.9. 1 Key Facts
- 12.9. 2 Business Description
- 12.9. 3 Products and Services
- 12.9. 4 Financial Overview
- 12.9. 5 SWOT Analysis
- 12.9. 6 Key Developments
- 12.10 Eli Lilly and Co
- 12.10. 1 Key Facts
- 12.10. 2 Business Description
- 12.10. 3 Products and Services
- 12.10. 4 Financial Overview
- 12.10. 5 SWOT Analysis
- 12.10. 6 Key Developments
- 13. Appendix
- 13.1 About Business Market Insights
- 13.2 List of Abbreviations
- TABLE OF TABLES
- Table 1. Colombia Cancer Therapeutics Market Segmentation
- Table 2. List of Vendors
- Table 3. Colombia Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million)
- Table 4. Colombia Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million)
- Table 5. Colombia Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million) – by Therapy Types
- Table 6. Colombia Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million) – by Therapy Types
- Table 7. Colombia Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million) – by Indications
- Table 8. Colombia Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million) – by Indications
- Table 9. Colombia Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million) – by Distribution Channel
- Table 10. Colombia Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million) – by Distribution Channel
- Table 11. List of Abbreviations
- TABLE OF FIGURES
- Figure 1. Impact Analysis of Drivers and Restraints
- Figure 2. Colombia Cancer Therapeutics Market Revenue, (US$ Million), 2021–2031
- Figure 3. Heat Map Analysis by Key Players
- Figure 4. Company Positioning and Concentration
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.